Junhyeong Yim

Junhyeong Yim

Auto-generated profile, based on publicly available information

Junhyeong Yim

Department of Chemistry, Kangwon National University, ChunCheon, Republic of Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
YSYoung‐Hee Shin
Young‐Hee Shin
KJKiyoung Jeong
Kiyoung Jeong
JLJihye Lee
Jihye Lee
HLHyo Jung Lee
Hyo Jung Lee
JYJunhyeong Yim
Junhyeong Yim
Seung Bum ParkSeung Bum Park
Seung Bum Park
The emergence of SARS‐CoV‐2 variants is a significant concern in developing effective therapeutics and vaccines in the middle of the ongoing COVID‐19 pandemic. Here, we have identified a novel small molecule that inhibited the interactions between SARS‐CoV‐2 spike RBDs and ACE2 by modulating ACE2 without impairing its enzymatic activity necessary for normal physiological functions. Furthermore, the identified compounds suppressed viral infection in cultured cells by inhibiting the entry of ancestral and variant SARS‐CoV‐2. Our study suggests that targeting ACE2 could be a novel therapeutic strategy to inhibit SARS‐CoV‐2 entry into host cells and prevent the development of COVID‐19.

13 March 2023 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
WCWansang Cho
Wansang Cho
SWSolchan Won
Solchan Won
YCYoona Choi
Yoona Choi
SYSihyeong Yi
Sihyeong Yi
JPJong Beom Park
Jong Beom Park
Seung Bum ParkSeung Bum Park
Seung Bum Park
Modulating target proteins via the ubiquitin‐proteasome system has recently expanded the scope of pharmacological inventions. Stimulator of interferon genes (STING) is an auspicious target for immunotherapy. Seminal studies envisioned the importance of STING as well as the utility of its agonists in immunotherapy outcomes. Herein, we suggest UPPRIS (upregulation of target proteins by protein‐protein interaction strategy) to pharmacologically increase cellular STING levels for improved immunotherapy. We discovered the small molecule SB24011 that inhibits STING‐TRIM29 E3 ligase interaction, thus blocking TRIM29‐induced degradation of STING. SB24011 enhanced STING immunity by upregulating STING protein levels, which robustly potentiated the immunotherapy efficacy of STING agonist and anti‐PD‐1 antibody via systemic anticancer immunity. Overall, we demonstrated that targeted protein upregulation of STING can be a promising approach for immuno‐oncology.

2 February 2024 in Chemical Science
Verified
Journal Article
Open access
PDF file
JYJunhyeong Yim
Junhyeong Yim
YHYoon Soo Hwang
Yoon Soo Hwang
JLJae-Jin Lee
Jae-Jin Lee
JKJu Hee Kim
Ju Hee Kim
JBJeong Yeob Baek
Jeong Yeob Baek
Seung Bum ParkSeung Bum Park
Seung Bum Park
Target identification using fluorescence difference in two-dimensional gel electrophoresis (FITGE) revealed the molecular mechanism of ICM that ameliorates PD by targeting a specific form of Keap1.

14 March 2022 in Frontiers in Chemistry
Verified
Journal Article
Open access
JYJunhyeong Yim
Junhyeong Yim
Seung Bum ParkSeung Bum Park
Seung Bum Park
Elucidation of the molecular mechanism of therapeutic agents and potential candidates is in high demand. Interestingly, rhenium-based complexes have shown a highly selective anticancer effect, only on cancer cells, unlike platinum-based drugs, such as cisplatin and carboplatin. These differences might be attributed to their different molecular targets. We confirmed that the target of tricarbonyl rhenium isonitrile polypyridyl (TRIP) complex is a protein, not DNA, using ICP-MS analysis and identified heat shock protein 60 (HSP60) as its target protein using a label-free target identification method. The subsequent biological evaluation revealed that TRIP directly inhibits the chaperone function of HSP60 and induces the accumulation of misfolded proteins in mitochondria, thereby leading to the activation of mitochondrial unfolded protein response (mtUPR)-mediated JNK2/AP-1/CHOP apoptotic pathway.

26 May 2026 in Nature Communications
Verified
Journal Article
Open access
JYJunhyeong Yim
Junhyeong Yim
JLJaeseok Lee
Jaeseok Lee
SKSolbi Kim
Solbi Kim
JCJieun Choi
Jieun Choi
SYSoyoung Yoon
Soyoung Yoon
JPJongmin Park
Jongmin Park
Despite the recent advancement of proteolysis-targeting chimera (PROTAC) development, they remain predominantly dependent on two E3 ligases, CRBN and VHL, which are ubiquitously expressed in all types of cells. Recently, efforts to discover tissue-specific E3 ligase ligands get attention as a promising strategy to enable tissue-specific protein degradation and avoid off-target tissue effects. Advancing this line of research, we discover a ligand of KLHL41, a muscle-specific E3 ligase, through virtual screening. Building on the KLHL41 ligand, we develop KBD-1, a muscle-specific BRD4-targeting PROTAC with micromolar activity. To enhance degradation efficiency, we employ a two-body kinetic strategy, resulting in the covalent PROTAC cKBD-1, which achieves sub-nanomolar activity. cKBD-1 demonstrates muscle-specific BRD4 degradation through KLHL41 recruitment both in vitro and in vivo. Moreover, the KLHL41 ligand enables AR-targeting PROTAC development, demonstrating its broad applicability. These findings highlight the potential of KLHL41 as a platform for tissue-specific protein degradation and its applicability in therapeutic development.

18 January 2022 in Angewandte Chemie
Verified
Journal Article
Closed access
PDF file
YSYoung‐Hee Shin
Young‐Hee Shin
KJKiyoung Jeong
Kiyoung Jeong
JLJihye Lee
Jihye Lee
HLHyo Jung Lee
Hyo Jung Lee
JYJunhyeong Yim
Junhyeong Yim
Seung Bum ParkSeung Bum Park
Seung Bum Park